Arvinas, Inc. announced promising preclinical results for ARV-393, a targeted protein degrader aimed at treating non-Hodgkin lymphoma, particularly high grade B-cell lymphomas. Data showed that ...

"Technology doesn’t just build the future — it defines it," said IBM CEO Arvind (NSE:ARVN) Krishna. "We have been focused on American jobs and manufacturing since our founding 114 years ago, and with ...

As of 2:58:31 PM EDT. Market Open.